According to naver news on July 16, the world’s largest tobacco company Philip Morris International intends to re-launch its heat-not-burn product “IQOS” in the United States, which has attracted widespread attention from U.S. health organizations. These organizations have expressed serious concerns about the potential harm of vapes and called on regulatory authorities to carefully approve it.
Six health organizations, including the American Academy of Pediatrics, the American Lung Association, and the Campaign for Tobacco-Free Kids, have submitted a letter of protest to the U.S. Food and Drug Administration (FDA), expressing concerns about the re-listing of IQOS vapes. These organizations pointed out that although Philip Morris International claims that IQOS helps people quit smoking, existing evidence shows that the product is not as effective as advertised in helping people quit smoking.
The protest letter mentioned that Philip Morris International Tobacco Company has repeatedly issued statements that may mislead the public, making people mistakenly believe that the FDA has confirmed that IQOS can reduce the risk of disease; plus the IQOS product implies that it is less harmful than traditional cigarettes, which violates the relevant FDA regulations; in addition, these health organizations also pointed out that Philip Morris International Tobacco Company’s statement that IQOS can prompt a large number of traditional smokers to switch to vape users lacks factual basis. They cited research data from the International Tobacco Control Project (ITC) of the University of Waterloo in Canada, showing that the smoking cessation rates of IQOS users in South Korea and Japan are 30% and 15% respectively, far lower than the 70% claimed by Philip Morris International Tobacco Company.
In response, Philip Morris International Tobacco Company responded that the company always abides by relevant laws and regulations when discussing science and products, and insisted that its statements are in line with FDA orders. The FDA approved Philip Morris International Tobacco Company to sell the old version of IQOS in 2019, but then issued a “risk modification” order requiring the company to improve its products to reduce the emission of hazardous chemicals. Last year, Philip Morris International Tobacco Company applied to launch the latest and improved IQOS model, but the FDA has not yet made a decision on whether to approve it for marketing.
In this context, Veehoo vape, as a brand focused on user health and product safety, continues to pay attention to and respond to these important issues in the market. Veehoo has always been committed to providing vape products that meet high quality standards and compliance requirements to ensure the health and safety of users.
Veehoo vape emphasizes transparency and reliability, and is committed to ensuring the quality of products through reasonable scientific research and strict quality control processes. Veehoo pays attention to user needs and potential health threats, and strives to provide a more stable and relatively safe alternative to smoking to help those who want to get rid of traditional tobacco products.
In this context of controversy and concern, Veehoo vape will continue to uphold its commitment to user health and safety, and is committed to providing high-quality, regulatory-compliant vape products to ensure that users have access to reliable smoking alternatives. Through continuous innovation and improvement, Veehoo will continue to provide users with a better vape experience, while paying attention to and complying with relevant regulations and specifications to create a better smoking choice for users.
Tags: Six major health organizations in the United States oppose IQOS，Philip Morris International launches “IQOS” in the United States，veehoo vape